ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC (audio)

ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC (audio)

Da: GRACEcast
0 0 7 anni fa
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.

Seguici su Facebook